Setmelanotide in patients aged 2-5 years with rare MC4R pathway-associated obesity (VENTURE): a 1 year, open-label, multicenter, phase 3 trial

Argente, J., Verge, C. F., Okorie, U., Fennoy, I., Kelsey, M. M., Cokkinias, C., Scimia, C., Lee, H.-M., & Farooqi, I. S. (2024). Setmelanotide in patients aged 2–5 years with rare MC4R pathway-associated obesity (VENTURE): a 1 year, open-label, multicenter, phase 3 trial. The Lancet Diabetes & Endocrinology. https://doi.org/10.1016/s2213-8587(24)00273-0

Authors:

Jesús Argente

Charles F Verge

Uzoma Okorie

Ilene Fennoy

Megan M Kelsey

Casey Cokkinias

Cecilia Scimia

Hak-Myung Lee

I Sadaf Farooqi

Affiliated Authors:

Ilene Fennoy